Home › NDC Lookup › RxCUI directory › RxCUI 2670451

Sitagliptin 50 MG Oral Tablet [Zituvio] — RxCUI 2670451

RxNorm drug concept · Semantic branded drug
RxCUI 2670451 Semantic branded drug · SBD ● Current RxNorm concept 6 FDA products 12 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2670451
Official nameSitagliptin 50 MG Oral Tablet [Zituvio]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asZituvio 50 MG Oral Tablet
FDA products mapped6
Package NDCs mapped12
Reported Medicaid activity (SDUD)134 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Sitagliptin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Sitagliptin helps your body manage blood sugar more effectively by keeping certain gut hormones active longer after you eat. Those hormones tell your pancreas to release more insul...
  • What exactly does sitagliptin do — and will it cure my diabetes?
  • On its own, sitagliptin is very unlikely to cause low blood sugar — that's actually one of its advantages. The reason is that it only kicks in when your blood sugar is already elev...
  • Can sitagliptin make my blood sugar go too low?
📖 Read our full Sitagliptin guide →

🕸️ Concept Web — How Sitagliptin 50 MG Oral Tablet [Zituvio] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Sitagliptin 50 MG Oral Tablet [Zituvio] RxCUI 2670451

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Sitagliptin 593411
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Zituvio 2670442
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Sitagliptin Oral Tablet 665032
    • Sitagliptin Oral Product 1159662
    • Sitagliptin Pill 1159663
    • Sitagliptin Oral Tablet [Zituvio] 2670446
    • Zituvio Oral Product 2670444
    • Zituvio Pill 2670445
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Sitagliptin 50 MG Oral Tablet SCD · 665042
  • Sitagliptin 50 MG SCDC · 665041
  • Sitagliptin Oral Tablet SCDF · 665032
  • Sitagliptin Oral Product SCDG · 1159662
  • Sitagliptin Pill SCDG · 1159663

Brand-Name Concepts

  • Sitagliptin 50 MG [Zituvio] SBDC · 2670450
  • Sitagliptin Oral Tablet [Zituvio] SBDF · 2670446
  • Zituvio Oral Product SBDG · 2670444
  • Zituvio Pill SBDG · 2670445
  • Zituvio BN · 2670442

📦 FDA Products & Package NDCs

6 products · 12 package NDCs
12 package NDCs map to RxCUI 2670451 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70710-1240-03 30 TABLET in 1 BOTTLE (70710-1240-3) ZITUVIO Zydus Pharmaceuticals (USA) Inc. 2023-11-30
70710-1240-09 90 TABLET in 1 BOTTLE (70710-1240-9) ZITUVIO Zydus Pharmaceuticals (USA) Inc. 2023-11-30
70710-1241-03 30 TABLET in 1 BOTTLE (70710-1241-3) ZITUVIO Zydus Pharmaceuticals (USA) Inc. 2023-11-30
70710-1241-09 90 TABLET in 1 BOTTLE (70710-1241-9) ZITUVIO Zydus Pharmaceuticals (USA) Inc. 2023-11-30
70710-1242-03 30 TABLET in 1 BOTTLE (70710-1242-3) ZITUVIO Zydus Pharmaceuticals (USA) Inc. 2023-11-30
70710-1242-09 90 TABLET in 1 BOTTLE (70710-1242-9) ZITUVIO Zydus Pharmaceuticals (USA) Inc. 2023-11-30
70771-1770-03 30 TABLET in 1 BOTTLE (70771-1770-3) ZITUVIO Zydus Lifesciences Limited 2023-11-30
70771-1770-09 90 TABLET in 1 BOTTLE (70771-1770-9) ZITUVIO Zydus Lifesciences Limited 2023-11-30
70771-1771-03 30 TABLET in 1 BOTTLE (70771-1771-3) ZITUVIO Zydus Lifesciences Limited 2023-11-30
70771-1771-09 90 TABLET in 1 BOTTLE (70771-1771-9) ZITUVIO Zydus Lifesciences Limited 2023-11-30
70771-1772-03 30 TABLET in 1 BOTTLE (70771-1772-3) ZITUVIO Zydus Lifesciences Limited 2023-11-30
70771-1772-09 90 TABLET in 1 BOTTLE (70771-1772-9) ZITUVIO Zydus Lifesciences Limited 2023-11-30
Observed labelers: Zydus Lifesciences Limited (6) · Zydus Pharmaceuticals (USA) Inc. (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.